C1 Esterase Inhibitor + Placebo
Phase 2/3Completed 0 watching 0 views this week📈 Rising
64
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hereditary Angioedema
Conditions
Hereditary Angioedema
Trial Timeline
Jun 1, 2005 → Dec 1, 2007
NCT ID
NCT00168103About C1 Esterase Inhibitor + Placebo
C1 Esterase Inhibitor + Placebo is a phase 2/3 stage product being developed by CSL for Hereditary Angioedema. The current trial status is completed. This product is registered under clinical trial identifier NCT00168103. Target conditions include Hereditary Angioedema.
Hype Score Breakdown
Clinical
22
Activity
15
Company
9
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00168103 | Phase 2/3 | Completed |
Competing Products
20 competing products in Hereditary Angioedema
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KVD900 | KalVista Pharmaceuticals | Phase 2 | 47 |
| KVD824 + Placebo to KVD824 | KalVista Pharmaceuticals | Phase 1 | 28 |
| KVD900 600 mg + KVD900 300 mg | KalVista Pharmaceuticals | Phase 3 | 72 |
| Sebetralstat | KalVista Pharmaceuticals | Pre-clinical | 18 |
| KVD900 + Placebo to KVD900 | KalVista Pharmaceuticals | Phase 1 | 28 |
| Sebetralstat | KalVista Pharmaceuticals | Pre-clinical | 18 |
| Placebo + KVD900 600 mg + KVD900 300 mg | KalVista Pharmaceuticals | Phase 3 | 72 |
| KVD824 Prototype 1 modified-release tablet + KVD824 Prototype 2 modified-release tablet + KVD824 Immediate-Release Capsule + Placebo to KVD824 Prototype 1 + KVD824 Prototype 3 modified-release tablet | KalVista Pharmaceuticals | Phase 1 | 28 |
| KVD900 150 mg + KVD900 300 mg + KVD900 600 mg | KalVista Pharmaceuticals | Phase 3 | 72 |
| KVD824 + Placebo to KVD824 | KalVista Pharmaceuticals | Phase 2 | 47 |
| KVD900 600 mg + Drug: KVD900 300 mg | KalVista Pharmaceuticals | Phase 3 | 72 |
| Deferasirox FCT | Novartis | Phase 2 | 52 |
| Canakinumab + Placebo | Novartis | Phase 3 | 77 |
| Ilaris | Novartis | Pre-clinical | 23 |
| Standard of Care for Haemophilia A | Roche | Pre-clinical | 23 |
| Emicizumab | Roche | Phase 3 | 77 |
| Tafamidis | Pfizer | Pre-clinical | 22 |
| tafamidis | Pfizer | Pre-clinical | 22 |
| Nitisinone | Swedish Orphan Biovitrum | Pre-clinical | 22 |
| Nitisinone | Swedish Orphan Biovitrum | Phase 1 | 32 |